ZGNX - Zogenix, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Zogenix, Inc.

5858 Horton Street
Suite 455
Emeryville, CA 94608
United States

Full Time Employees90

Key Executives

NameTitlePayExercisedYear Born
Dr. Stephen J. FarrCo-Founder, CEO, Pres & Director869.7k12.51k1959
Mr. Michael P. SmithExec. VP, CFO, Treasurer & Sec.572.33kN/A1968
Dr. Bradley S. GalerExec. VP & Chief Medical Officer587.95kN/A1962
Dr. Gail M. FarfelExec. VP & Chief Devel. Officer574.1k867.89k1964
Mr. Ashish M. SagrolikarExec. VP & Chief Commercial Officer557.7kN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.

Corporate Governance

Zogenix, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 6. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.